Note 11 - Accrued Expenses

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

11.

Accrued Expenses

Accrued expenses consist of the following:

	December 31,
	2018		2017
Compensation and related expenses	$	4,446	$	2,893
Professional fees		1,989		448
Voluntary recall		116		-
Research grants		400		419
Clinical trial costs		577		2,318
Income taxes payable		385		-
Other		233		248
Total	$	8,146	$	6,326

Included in Compensation and related expenses as of

December 31, 2018

are the accrued and unpaid costs related to the retirement of the Company’s former Chief Executive Officer as of

March 9, 2018.

On

March 8, 2018

the Company entered into a

$0.3

million

one

-year, post-retirement consulting agreement with the former Chief Executive Officer to provide certain services as

may

be requested by the Company through

February 28, 2019.

On the same date, the Company and the former Chief Executive Officer entered into a release agreement related to terms in his employment agreement. Under the terms of these agreements, the former Chief Executive Officer is entitled to receive from the Company, as a result of his retirement, aggregate benefits of

$1.7

million over the

18

-month period subsequent to

March 9, 2018,

among other benefits. As more fully described in Note

13,

all of the former Chief Executive Officer’s outstanding equity awards vested in full and became exercisable upon his retirement.

Accrued liabilities related to the previously-described product recall of certain production lots of the Company’s HYAFF-based products, more fully described in Note

3,

includes an accrual as of

December 31, 2018

of

$0.1

million of expenses associated with the administration and remediation of the voluntary recall.